Keyword: Viekira Pak

Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.

Veterans are far more likely to have hepatitis C, and Merck—which makes the antiviral therapy Zepatier—wants to make sure they know that.

Get set for even more competition in the hep C space as AbbVie picked up FDA approval for Mavyret.

AbbVie turned in better-than-expected second quarter results, but investors remained focused on whether pipeline prospects will make up for the eventual decline of Humira.

Armed with a revamped deal-scouting team, Gilead is eyeing oncology—and it isn't fazed by turbulence in Washington, CEO John Milligan said on Tuesday.

With anticipated generics, Express Scripts is looking to save on GlaxoSmithKline’s big-selling Advair.

AbbVie investors were relieved when the company announced first-quarter results that exceeded forecasts, driven largely by an increase in Humira sales.

Gilead has unveiled new advertising for hep C drug Harvoni, replacing its introductory ad with a spot that highlights three key words: "I am cured."

Patient-access groups that have targeted Gilead's Sovaldi IP all over the world are back on the attack in Europe.